Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling

Although conventional therapies for acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) are effective in inducing remission, many patients relapse upon treatment. Hence, there is an urgent need for novel therapies. PIM kinases are often overexpressed in AML and DLBCL and are there...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunen, Diede, García-Barchino, María José, Malani, Disha, Basheer, Noorjahan Jagalur, Lieftink, Cor, Beijersbergen, Roderick L., Murumägi, Astrid, Porkka, Kimmo, Wolf, Maija, Zwaan, C. Michel, Fornerod, Maarten, Kallioniemi, Olli, Martínez-Climent, José Ángel, Bernards, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122321/
https://www.ncbi.nlm.nih.gov/pubmed/27270648
http://dx.doi.org/10.18632/oncotarget.9822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122321/
https://www.ncbi.nlm.nih.gov/pubmed/27270648
http://dx.doi.org/10.18632/oncotarget.9822

Ejemplares similares